Standout Papers

Continuation of bevacizumab after first progression in metastat... 2005 2026 2012 2019 809
  1. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial (2012)
    Jaafar Bennouna, Javier Sastre et al. The Lancet Oncology
  2. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial (2005)
    R. Jakesz, W. Jonat et al. The Lancet
  3. Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer (2009)
    José Baselga, Semiglazov Vf et al. Journal of Clinical Oncology
  4. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial (2018)
    Carol Moreno, Richard Greil et al. The Lancet Oncology
  5. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial (2020)
    Vivek Subbiah, Ulrik Lassen et al. The Lancet Oncology
  6. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study (2022)
    Luca Gianni, Chiun‐Sheng Huang et al. Annals of Oncology

Immediate Impact

8 by Nobel laureates 9 from Science/Nature 78 standout
Sub-graph 1 of 21

Citing Papers

Pancreatic cancer
2025 Standout
Bacterial immunotherapy leveraging IL-10R hysteresis for both phagocytosis evasion and tumor immunity revitalization
2025 Standout
3 intermediate papers

Works of Richard Greil being referenced

Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)
2021
Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: A single institution retrospective review
2013

Author Peers

Author Last Decade Papers Cites
Richard Greil 10588 3989 4049 5190 716 19.5k
Bernd Dörken 8532 2229 4708 8541 412 21.6k
Naoto T. Ueno 10744 3626 2171 5453 537 19.9k
Apostolia M. Tsimberidou 5251 3207 3336 4683 440 13.9k
Jonathan Said 8161 5105 4407 8355 370 20.2k
Christoph Zielinski 9866 5567 1367 4938 497 20.3k
Patricia LoRusso 10965 4274 1938 10660 560 21.3k
Gianni Bonadonna 11190 3803 7387 2101 363 19.9k
Anas Younes 10689 2651 11335 6399 525 21.6k
Richard S. Houlston 6383 2283 7108 8494 464 20.1k
David S. Hong 10195 6145 2645 9319 810 22.5k

All Works

Loading papers...

Rankless by CCL
2026